FGP
Freestone Grove Partners Portfolio holdings
AUM
$15.6B
Turnover
60.27%
1-Year Est. Return
27.39%
This Fund
S&P 500
This Quarter
Est. Return
+0.81%
1 Year Est. Return
+27.39%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$14.2B
AUM Growth
+$326M
(+2.4%)
Cap. Flow
+$206M
Cap. Flow
% of AUM
1.46%
Top 10 Holdings %
Top 10 Hldgs %
19%
Holding
1,229
New
515
Increased
214
Reduced
228
Closed
267
Avg Time Held Equity + Options
0.3
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.1
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Citigroup
C
|
+$134M |
| 2 |
Pinnacle Financial Partners Inc
PNFP
|
+$120M |
| 3 |
KKR & Co
KKR
|
+$113M |
| 4 |
Mondelez International
MDLZ
|
+$103M |
| 5 |
AXIS Capital
AXS
|
+$97.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$303M |
| 2 |
Boston Scientific
BSX
|
+$127M |
| 3 |
Lennar Class A
LEN
|
+$95.9M |
| 4 |
Martin Marietta Materials
MLM
|
+$94.6M |
| 5 |
Colgate-Palmolive
CL
|
+$92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.98% |
| 2 | Technology | 14.39% |
| 3 | Miscellaneous | 12.72% |
| 4 | Industrials | 12.27% |
| 5 | Healthcare | 11.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
801
Arcutis Biotherapeutics
ARQT
$3.35B
| $107K | ﹤0.01% |
+4,543
| New | +$116K |
2026 Q1
0 quarters
|
|
802
Simpson Manufacturing
SSD
$6.97B
| $102K | ﹤0.01% |
+594
| New | +$110K |
2026 Q1
0 quarters
|
|
803
Azenta
AZTA
$1.66B
| $99.3K | ﹤0.01% |
+4,698
| New | +$140K |
2026 Q1
0 quarters
|
|
804
Certara
CERT
$1.44B
| $98.7K | ﹤0.01% |
+17,312
| New | +$132K |
2026 Q1
0 quarters
|
|
805
Grocery Outlet
GO
$1.23B
| $98.6K | ﹤0.01% |
13,989
-679
| -5% | -$5.9K |
2025 Q4
1 quarter
|
|
806
DELISTED
BioLife Solutions
BLFS
| $98.5K | ﹤0.01% |
+5,163
| New | +$114K |
2026 Q1
0 quarters
|
|
807
Adtran
ADTN
$543M
| $97.3K | ﹤0.01% |
7,731
-2,291
| -23% | -$23.2K |
2025 Q4
1 quarter
|
|
808
NewAmsterdam Pharma
NAMS
$2.41B
| $96K | ﹤0.01% |
+3,000
| New | +$97.7K |
2026 Q1
0 quarters
|
|
809
Dell
DELL
$323B
| $95.4K | ﹤0.01% |
+581
| New | +$77.4K |
2026 Q1
0 quarters
|
|
810
Arlo Technologies
ARLO
$1.28B
| $92.5K | ﹤0.01% |
6,501
-21,290
| -77% | -$285K |
2025 Q4
1 quarter
|
|
811
SBA Communications
SBAC
$19B
| $90.9K | ﹤0.01% |
+528
| New | +$99K |
2026 Q1
0 quarters
|
|
812
WaFd
WAFD
$2.15B
| $90.6K | ﹤0.01% |
+2,886
| New | +$92.8K |
2026 Q1
0 quarters
|
|
813
Harmonic Inc
HLIT
$1.11B
| $88.8K | ﹤0.01% |
+9,888
| New | +$98.2K |
2026 Q1
0 quarters
|
|
814
Ameresco
AMRC
$1.07B
| $87.7K | ﹤0.01% |
+3,440
| New | +$103K |
2026 Q1
0 quarters
|
|
815
Chefs' Warehouse
CHEF
$4.5B
| $86.9K | ﹤0.01% |
+1,461
| New | +$93.5K |
2026 Q1
0 quarters
|
|
816
Kura Sushi USA
KRUS
$467M
| $82.5K | ﹤0.01% |
+1,182
| New | +$79.3K |
2026 Q1
0 quarters
|
|
817
Arbutus Biopharma
ABUS
$828M
| $81K | ﹤0.01% |
+18,006
| New | +$78.7K |
2026 Q1
0 quarters
|
|
818
CareDx
CDNA
$3.38B
| $76.7K | ﹤0.01% |
+4,416
| New | +$83.6K |
2026 Q1
0 quarters
|
|
819
XPEL
XPEL
$1.24B
| $74.5K | ﹤0.01% |
+1,683
| New | +$80.4K |
2026 Q1
0 quarters
|
|
820
Xenia Hotels & Resorts
XHR
$1.68B
| $73.3K | ﹤0.01% |
+4,941
| New | +$74.4K |
2026 Q1
0 quarters
|
|
821
GigaCloud Technology
GCT
$2.05B
| $72.3K | ﹤0.01% |
+1,594
| New | +$64.8K |
2026 Q1
0 quarters
|
|
822
Ingles Markets
IMKTA
$1.62B
| $70.6K | ﹤0.01% |
+785
| New | +$63.6K |
2026 Q1
0 quarters
|
|
823
CorMedix
CRMD
$575M
| $70.2K | ﹤0.01% |
+10,332
| New | +$76.4K |
2026 Q1
0 quarters
|
|
824
Northwest Natural Holdings
NWN
$2.05B
| $68.2K | ﹤0.01% |
+1,282
| New | +$63.5K |
2026 Q1
0 quarters
|
|
825
Liberty Energy
LBRT
$2.92B
| $67.6K | ﹤0.01% |
2,346
-345,879
| -99% | -$8.82M |
2025 Q4
1 quarter
|
|
Similar funds
ECM
MIFH
GF
AIM
OTPPB
AA
IWC
Freestone Grove Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Freestone Grove Partners held 1,229 positions worth $14.2B, up 2.4% from $13.8B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Freestone Grove Partners's Q1 2026 filing shows 515 new, 214 increased, 228 reduced and 267 closed positions. Its largest new stake was Citigroup: 1,180,436 shares worth $134M. The largest sale was iShares Core S&P 500 ETF, an estimated $303M.
By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 15% a quarter earlier, followed by Technology and Miscellaneous.
- Freestone Grove Partners's largest Q1 2026 buy was Citigroup: 1,180,436 shares worth $134M.
- Freestone Grove Partners added most to AXIS Capital in Q1 2026, an estimated $97.1M increase.
- Freestone Grove Partners's biggest Q1 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $303M.
- Freestone Grove Partners fully exited Boston Scientific in Q1 2026, selling an estimated $127M.
- Freestone Grove Partners's ten largest holdings make up 19% of its $14.2B portfolio in Q1 2026.
- Freestone Grove Partners opened 515 new positions and closed 267 in Q1 2026.
- Freestone Grove Partners's portfolio value rose 2.4% quarter-over-quarter to $14.2B.
Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.